Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 30:13:509.
doi: 10.1186/1471-2334-13-509.

Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions

James I Brooks  1 , Harrison Niznick, Marianna Ofner, Harriet Merks, Jonathan B Angel
Affiliations

Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions

James I Brooks et al. BMC Infect Dis. .

Abstract

Background: HIV transmitted drug resistance (TDR) surveillance is usually conducted by sampling from a large population. However, overall TDR prevalence results may be inaccurate for many individual clinical setting. We analyzed HIV genotypes at a tertiary care setting in Ottawa, Ontario in order to evaluate local TDR patterns among sub-populations.

Method: Genotyping reports were digitized from ART naïve patients followed at the Immunodeficiency Clinic at the Ottawa Hospital, between 2008 and 2010. Quality controlled, digitized sequence data were assessed for TDR using the Stanford HIV Database. Patient characteristics were analyzed according to TDR patterns. Finally, a phylogenetic tree was constructed to elucidate the observed pattern of HIV TDR.

Results: Among the 155 clinic patients there was no statistically significantly difference in demographics as compared to the Ontario provincial HIV population. The clinic prevalence of TDR was 12.3%; however, in contrast to the data from Ontario, TDR patterns were inverted with a 21% prevalence among MSM and 5.5% among IDU. Furthermore, nearly 80% of the observed TDR was a D67N/K219Q pattern with 87% of these infections arising from a distinct phylogenetic cluster.

Conclusions: Local patterns of TDR were distinct to what had been observed provincially. Phylogenetic analysis uncovered a cluster of related infections among MSM that appeared more likely to be recent infections. Results support a paradigm of routine local TDR surveillance to identify the sub-populations under care. Furthermore, the routine application of phylogenetic analysis in the TDR surveillance context provides insights into how best to target prevention strategies; and how to correctly measure outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Maximum likelihood tree of HIV pol sequences generated using GTR model in PHYML with 100 bootstrap replicates. Sequences were trimmed to 986 bp with identified TDR mutation codons removed. 155 study cohort sequences are present in a background of 255 sequences further described in the methods. Orange box shows the D67N/K219Q cluster that was identified. For comparison purposes another cluster identified in the study cohort is identified in blue. ** Indicates the out-group N sequence N.CM.97.YBF106.
See this image and copyright information in PMC

References

    1. Palella FJ, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT. HOPS (HIV Outpatient Study) Investigators: The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009;151:73–84. doi: 10.7326/0003-4819-151-2-200907210-00003. - DOI - PubMed
    1. DeGruttola V, Dix L, D’Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiver Ther. 2000;5:41–48. - PubMed
    1. Méchai F, Quertainmont Y, Sahali S, Delfraissy J-F, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol. 2007;80:9–10. - PubMed
    1. Beltrami EM, Luo C-C, La Torre de N, Cardo DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol. 2002;23:345–348. doi: 10.1086/502065. - DOI - PubMed
    1. Vercauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit J-C, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme A-M, Boucher CAB. Transmission of Drug‒Resistant HIV‒1 Is Stabilizing in Europe. J Infect Dis. 2009;200:1503–1508. doi: 10.1086/644505. - DOI - PubMed

Substances

Associated data